gray bg blue bg

New Study for T2D Patients currently taking Trulicity

Please fill in your details

Please enter first name.
Please enter last name.
Please enter valid email.
Please enter valid contact number.
Please select type of diabetes.
Kindly fill in above all mandatory fields

About the Study


This study is for participants with Type 2 Diabetes currently taking Trulicity at a dose of 0.75 mg or 1.5 mg. Participants will either go on a higher dose of Trulicity or switch to Tirzepatide (Mounjaro). Mounjaro is a once-weekly injection for Type 2 Diabetes. The purpose of the study is to compare changes in A1C and weight loss.

Participants will receive the study med at no charge, and will be compensated for their time and travel.

Participant Eligibility Criteria ( To take part in the study )

  • Type 2 Diabetes
  • Currently taking Trulicity (0.75 mg or 1.5 mg)
  • A1C between 7.0% and 9.5%
  • Not using insulin

Please fill in your details

Please enter first name.
Please enter last name.
Please enter valid email.
Please enter valid contact number.
Please select type of diabetes.
Kindly fill in above all mandatory fields